Racial disparities in characteristics and outcomes of patients undergoing mitral transcatheter edge-to-edge repair

Background There are scarce data regarding the post-mitral transcatheter edge-to-edger repair (TEER) course in different racial groups. Objective To assess the impact of race on outcomes following TEER for mitral regurgitation (MR). Methods This is a single-center, retrospective analysis of consecutive TEER procedures performed during 2013–2020. The primary outcome was the composite of all-cause mortality or heart failure (HF) hospitalizations along the first postprocedural year. Secondary outcomes included individual components of the primary outcome, New York Heart Association (NYHA) class, MR grade, and left ventricular mass index (LVMi). Results Out of 964 cases, 751 (77.9%), 88 (9.1%), 68 (7.1%), and 57 (5.9%) were whites, blacks, Asians, and Hispanics, respectively. At baseline, non-whites and blacks were younger and more likely be female, based in lower socioeconomic areas, not fully insured, diagnosed with functional MR, and affected by biventricular dysfunction. Intra-procedurally, more devices were implanted in blacks. At 1-year, non-whites (vs. whites) and blacks (vs. non-blacks or whites) experienced higher cumulative incidence of the primary outcome (32.9% vs. 22.5%, p = 0.002 and 38.6% vs. 23.4% or 22.5%, p = 0.002 or p = 0.001, respectively), which were accounted for by hospitalizations in the functional MR sub-cohort (n = 494). NYHA class improved less among blacks with functional MR. MR severity and LVMi equally regressed in all groups. White race (HR 0.62, 95% CI 0.39–0.99, p = 0.047) and black race (HR 2.07, 95% CI 1.28–3.35, p = 0.003) were independently associated with the primary outcome in functional MR patients only. Conclusion Mitral TEER patients of different racial backgrounds exhibit major differences in baseline characteristics. Among those with functional MR, non-whites and blacks also experience a less favorable 1-year clinical outcome.

[1]  Jeroen J. Bax,et al.  Outcomes After Transcatheter Edge-to-Edge Mitral Valve Repair According to Mitral Regurgitation Etiology and Cardiac Remodeling. , 2022, JACC. Cardiovascular interventions.

[2]  J. Pankow,et al.  Racial and Ethnic Differences in All-Cause and Cardiovascular Disease Mortality: The MESA Study , 2022, Circulation.

[3]  Robert M. Minutello,et al.  Racial Disparities in Access to High-Volume Mitral Valve Transcatheter Edge-to-Edge Repair Centers , 2022, Journal of the Society for Cardiovascular Angiography & Interventions.

[4]  A. Regueiro,et al.  A Score to Assess Mortality After Percutaneous Mitral Valve Repair. , 2022, Journal of the American College of Cardiology.

[5]  L. Sposato,et al.  Racial, ethnic and socioeconomic disparities in patients undergoing transcatheter mitral edge-to-edge repair. , 2021, International journal of cardiology.

[6]  B. Prendergast,et al.  2021 ESC/EACTS Guidelines for the management of valvular heart disease. , 2021, European heart journal.

[7]  Harjit Singh,et al.  Trends, Predictors and In-Hospital Outcomes of the Next Day Discharge Approach After Transcatheter Mitral Valve Repair. , 2021, American Journal of Cardiology.

[8]  P. Denti,et al.  Implantation of one, two or multiple MitraClips for transcatheter mitral valve repair: insights from a 1824-patient multicenter study. , 2021, Panminerva Medica (Testo stampato).

[9]  S. Solomon,et al.  Effectiveness of angiotensin-neprilysin inhibitor treatment versus renin-angiotensin system blockade in older adults with heart failure in clinical care , 2021, Heart.

[10]  L. Sposato,et al.  Racial, ethnic and socioeconomic disparities in patients undergoing left atrial appendage closure , 2021, Heart.

[11]  P. Denti,et al.  Italian Society of Interventional Cardiology (GIse) registry Of Transcatheter treatment of mitral valve regurgitaTiOn (GIOTTO): impact of valve disease aetiology and residual mitral regurgitation after MitraClip implantation , 2021, European journal of heart failure.

[12]  M. Mack,et al.  2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2020, Circulation.

[13]  S. Lirette,et al.  Racial and Sex Differences in the Response to First-Line Antihypertensive Therapy , 2020, Frontiers in Cardiovascular Medicine.

[14]  M. Mack,et al.  2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2020, Journal of the American College of Cardiology.

[15]  G. Lloyd,et al.  Racial Differences In the Aetiology of Mitral Valve Disease. , 2020, European heart journal. Quality of care & clinical outcomes.

[16]  H. Jneid,et al.  Racial disparities in the utilization and outcomes of transcatheter mitral valve repair: Insights from a national database. , 2020, Cardiovascular revascularization medicine : including molecular interventions.

[17]  D. Holmes,et al.  Racial Disparities in the Utilization and Outcomes of Structural Heart Disease Interventions in the United States , 2019, Journal of the American Heart Association.

[18]  J. Carroll,et al.  Racial Disparities in the Utilization and Outcomes of TAVR: TVT Registry Report. , 2019, JACC. Cardiovascular interventions.

[19]  N. Weissman,et al.  Guidelines for the Evaluation of Valvular Regurgitation After Percutaneous Valve Repair or Replacement: A Report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Angiography and Interventions, Japanese Society of Echocardiography, and Socie , 2019, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[20]  M. Mack,et al.  Transcatheter Mitral‐Valve Repair in Patients with Heart Failure , 2018, The New England journal of medicine.

[21]  J. Spence,et al.  Hypertension in Blacks: Individualized Therapy Based on Renin/Aldosterone Phenotyping , 2018, Hypertension.

[22]  C. Denson The MESA Study. , 2017 .

[23]  Yuchi Han,et al.  Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation: A Report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance. , 2017, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[24]  M. Mack,et al.  Randomized Comparison of Percutaneous Repair and Surgery for Mitral Regurgitation: 5-Year Results of EVEREST II. , 2015, Journal of the American College of Cardiology.

[25]  G. Filippatos,et al.  Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 2: Endpoint Definitions: A Consensus Document From the Mitral Valve Academic Research Consortium. , 2015, Journal of the American College of Cardiology.

[26]  Keith C. Norris,et al.  African Americans, hypertension and the renin angiotensin system. , 2014, World journal of cardiology.

[27]  Jean-Louis Vanoverschelde,et al.  EAE/ASE recommendations for the use of echocardiography in new transcatheter interventions for valvular heart disease. , 2011, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[28]  Saibal Kar,et al.  Percutaneous repair or surgery for mitral regurgitation. , 2011, The New England journal of medicine.

[29]  A. Galloway,et al.  Mitral valve disease presentation and surgical outcome in African-American patients compared with white patients. , 2008, The Annals of thoracic surgery.